MYL
$38.94
Mylan Nv Ord Shs
($1.31)
(3.25%)
MYL
Earnings Whisper ®
N/A
1st Quarter March 2018
Consensus:  $0.99
Revenue:  $2.83 Bil
Wednesday
May 30
4:35 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Wednesday, February 28, 2018

What do you expect when MYL reports earnings?
Beat
Meet
Miss

Where is MYL's stock price going from here?
Up
Flat
Down
Stock chart of MYL
Analysts
Summary of analysts' recommendations for MYL
Score
Grade
Pivots
Resistance
$41.62
$40.89
$39.91

$39.18

Support
$38.20
$37.47
$36.49
Tweet
Growth
Description
Mylan Inc. is one of the world's leading quality generic and specialty pharmaceutical companies. The Company offers one of the industry's broadest and highest quality product portfolios, a robust product pipeline and a global commercial footprint through operations in more than 90 countries. Through its controlling interest in Matrix Laboratories Limited, Mylan has direct access to one of the largest active pharmaceutical ingredient manufacturers in the world. Dey L.P., Mylan's fully integrated specialty business, provides the Company with innovative and diversified opportunities in the respiratory and allergy therapeutic areas.
Peers
CelgeneRegeneron PharmaceuticalsEndo International plcVertex PharmaceuticalsBioMarin PharmaceuticalJohnson & JohnsonUltragenyx PharmaceuticalZoetisInterCeptPerrigo